

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index, the Asia Pacific version of the Dow Jones Sustainability Indices (“DJSI”) and one of the world’s premier indices for Socially Responsible Investment (“SRI”).

The DJSI, launched jointly by Dow Jones & Company of the United States and RobecoSAM AG of Switzerland, is a leading SRI index which assesses and selects leading sustainability-driven companies in terms of economic, environmental, and social criteria.

Specifically designed for companies in the developed Asia Pacific markets including Japan, the Dow Jones Sustainability Asia Pacific Index has selected 146 companies, including 68 Japanese companies, which are leading the way in terms of sustainability among approximately 600 companies in the region.

In addition to the DJSI, Astellas has also been selected for the fifth consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for SRI.

Astellas will continue to fulfill its corporate social responsibilities through a range of corporate activities including the provision of pharmaceutical products to address unmet medical needs, and will remain committed to supporting the sustainable development of society and consequently enhancing its enterprise value.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new

technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

###

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 http://www.astellas.com/en